» Articles » PMID: 38304231

Investigation of Protein-protein Interactions and Hotspot Region on the NSP7-NSP8 Binding Site in NSP12 of SARS-CoV-2

Abstract

The RNA-dependent RNA polymerase (RdRp) complex, essential in viral transcription and replication, is a key target for antiviral therapeutics. The core unit of RdRp comprises the nonstructural protein NSP12, with NSP7 and two copies of NSP8 (NSP81 and NSP82) binding to NSP12 to enhance its affinity for viral RNA and polymerase activity. Notably, the interfaces between these subunits are highly conserved, simplifying the design of molecules that can disrupt their interaction. We conducted a detailed quantum biochemical analysis to characterize the interactions within the NSP12-NSP7, NSP12-NSP81, and NSP12-NSP82 dimers. Our objective was to ascertain the contribution of individual amino acids to these protein-protein interactions, pinpointing hotspot regions crucial for complex stability. The analysis revealed that the NSP12-NSP81 complex possessed the highest total interaction energy (TIE), with 14 pairs of residues demonstrating significant energetic contributions. In contrast, the NSP12-NSP7 complex exhibited substantial interactions in 8 residue pairs, while the NSP12-NSP82 complex had only one pair showing notable interaction. The study highlighted the importance of hydrogen bonds and π-alkyl interactions in maintaining these complexes. Intriguingly, introducing the RNA sequence with Remdesivir into the complex resulted in negligible alterations in both interaction energy and geometric configuration. Our comprehensive analysis of the RdRp complex at the protein-protein interface provides invaluable insights into interaction dynamics and energetics. These findings can guide the design of small molecules or peptide/peptidomimetic ligands to disrupt these critical interactions, offering a strategic pathway for developing effective antiviral drugs.

Citing Articles

Redefining activity in SARS-CoV-2 and its regulation by and .

Singh D, Kushwaha T, Kulandaisamy R, Kumar V, Baswal K, Tiwari S Mol Ther Nucleic Acids. 2025; 36(1):102452.

PMID: 39944792 PMC: 11816038. DOI: 10.1016/j.omtn.2025.102452.


Quantum biochemical analysis of the TtgR regulator and effectors.

de Carvalho Matias E, Bezerra K, Costa A, Clemente Junior W, Oliveira J, Junior L Sci Rep. 2024; 14(1):8519.

PMID: 38609407 PMC: 11015042. DOI: 10.1038/s41598-024-58441-9.

References
1.
Lima Neto J, Vieira D, de Andrade J, Fulco U . Exploring the Spike-hACE 2 Residue-Residue Interaction in Human Coronaviruses SARS-CoV-2, SARS-CoV, and HCoV-NL63. J Chem Inf Model. 2022; 62(11):2857-2868. DOI: 10.1021/acs.jcim.1c01544. View

2.
Charness M, Gupta K, Stack G, Strymish J, Adams E, Lindy D . Rebound of SARS-CoV-2 Infection after Nirmatrelvir-Ritonavir Treatment. N Engl J Med. 2022; 387(11):1045-1047. PMC: 9511633. DOI: 10.1056/NEJMc2206449. View

3.
Morais P, Maia Jr F, Solis-Calero C, Caetano E, Freire V, Carvalho H . The urokinase plasminogen activator binding to its receptor: a quantum biochemistry description within an in/homogeneous dielectric function framework with application to uPA-uPAR peptide inhibitors. Phys Chem Chem Phys. 2020; 22(6):3570-3583. DOI: 10.1039/c9cp06530j. View

4.
Ruan Z, Liu C, Guo Y, He Z, Huang X, Jia X . SARS-CoV-2 and SARS-CoV: Virtual screening of potential inhibitors targeting RNA-dependent RNA polymerase activity (NSP12). J Med Virol. 2020; 93(1):389-400. PMC: 7361265. DOI: 10.1002/jmv.26222. View

5.
Gu Y, Liu M, Staker B, Buchko G, Quinn R . Drug-Repurposing Screening Identifies a Gallic Acid Binding Site on SARS-CoV-2 Non-structural Protein 7. ACS Pharmacol Transl Sci. 2023; 6(4):578-586. PMC: 10111621. DOI: 10.1021/acsptsci.2c00225. View